DAPTOMYCIN IN 0.9% SODIUM CHLORIDE (Daptomycin) Patent Expiration, LOE Window & CMS Spending
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE (Daptomycin) by Baxter Healthcare: FDA Orange Book core substance LOE 2041-03-11, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Baxter Healthcare |
| FDA Application & Pathway | N213645 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2041-03-11 |
| Last Listed Patent or Exclusivity Date | 2041-03-11 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Baxter International across sibling Meru public-data platforms.